Head and neck squamous cell carcinomas (HNSCC) are the seventh-most prevalent form of cancer and are associated with human ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell ...

Head and neck squamous cell carcinoma (HNSCC) remains a clinical challenge owing to its heterogeneity and often unfavourable outcomes. Recent developments have underscored the importance of ...

Functional and survival outcomes in HPV positive oropharyngeal squamous cell cancer treated with response-adaptive de-escalation: A pooled analysis. This is an ASCO Meeting Abstract from the 2025 ASCO ...

There are three common types of skin cancer in the United States: basal cell carcinoma, squamous cell carcinoma and melanoma. Merkel cell carcinoma is a rare type of skin cancer. Fred Hutch Cancer ...